Impact of formulary restriction with prior authorization by an antimicrobial stewardship program

Virulence

Volumn 4, Issue 2, 2013, Pages 158-162

  Reed, Erica E ^a   Stevenson, Kurt B ^b,c   West, Jessica E ^b   Bauer, Karri A ^a   Goff, Debra A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial stewardship; Costs; Doripenem; Formulary restriction; Prior authorization

Indexed keywords

CARBAPENEM; COLISTIN; DAPTOMYCIN; DORIPENEM; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER; ANTIMICROBIAL STEWARDSHIP PROGRAM; ARTICLE; DRUG APPROVAL; DRUG FORMULARY; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; MEDICAL RECORD; PHYSICIAN; PSEUDOMONAS; QUALITY CONTROL;

EID: 84874215662     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.21657     Document Type: Article

References (32)

1. Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011; 53(Suppl 1):S4-7. PMID:21795727; http://dx.doi.org/10.1093/cid/cir362.
2. http://www.cdc.gov/getsmart/healthcare/. Accessed 15 April 2012.
3. Dellit TH, Owens RC, McGowan JE Jr., Gerding DN, Weinstein RA, Burke JP, et al.; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77. PMID:17173212; http://dx.doi.org/10.1086/510393.
4. Drew RH, White R, MacDougall C, Hermsen ED, Owens RC Jr.; Society of Infectious Diseases Pharmacists. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy 2009; 29:593-607. PMID:19397466; http://dx.doi.org/10.1592/phco.29.5.593.
5. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18:638-56. PMID:16223951; http://dx.doi.org/10.1128/CMR.18.4.638-656.2005.
6. LaRosa LA, Fishman NO, Lautenbach E, Koppel RJ, Morales KH, Linkin DR. Evaluation of antimicrobial therapy orders circumventing an antimicrobial stewardship program: investigating the strategy of "stealth dosing". Infect Control Hosp Epidemiol 2007; 28:551-6. PMID:17464914; http://dx.doi.org/10.1086/513535.
7. Burke JP. Antibiotic resistance--squeezing the balloon? JAMA 1998; 280:1270-1. PMID:9786379; http://dx.doi.org/10.1001/jama.280.14.1270.
8. st Interscience Conference on Antimicrobial Agents and Chemotherapy: September 2011; Chicago, IL.
9. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33:289-95. PMID:11438891; http://dx.doi.org/10.1086/321880
10. Linkin DR, Paris S, Fishman NO, Metlay JP, Lautenbach E. Inaccurate communications in telephone calls to an antimicrobial stewardship program. Infect Control Hosp Epidemiol 2006; 27:688-94. PMID:16807843; http://dx.doi.org/10.1086/505918.
11. West JA, Reed EE, Taylor J, Stevenson K. Impact of doripenem formulary restriction [abstract]. Presented at: The 49th Annual Meeting of the Infectious Diseases Society of America: October 2011; Boston, Massachusetts.
12. Stevenson KB, Balada-Llasat JM, Bauer K, Deutscher M, Goff D, Lustberg M, et al. The economics of antimicrobial stewardship: the current state of the art and applying the business case model. Infect Control Hosp Epidemiol 2012; 33:389-97. PMID:22418635; http://dx.doi.org/10.1086/664910.
13. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med 1991; 90:439-44. PMID:1901446.
14. Woodward RS, Medoff G, Smith MD, Gray JL 3rd. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987; 83:817-23. PMID:3674089;http://dx.doi.org/10.1016/0002-9343(87)90636-X.
15. Seligman SJ. Reduction in antibiotic costs by restricting use of an oral cephalosporin. Am J Med 1981; 71:941-4. PMID:7315856; http://dx.doi.org/10.1016/0002-9343(81)90304-1.
16. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010; 51:1074-80. PMID:20879856; http://dx.doi.org/10.1086/656623.
17. White AC Jr., Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9. PMID:9332517; http://dx.doi.org/10.1086/514545.
18. Martin C, Ofotokun I, Rapp R, Empey K, Armitstead J, Pomeroy C, et al. Results of an antimicrobial controlprogram at a university hospital. Am J Health Syst Pharm 2005; 62:732-8. PMID:15790801.
19. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7. PMID:9786372; http://dx.doi.org/10.1001/jama.280.14.1233.
20. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycinresistant enterococci. Clin Infect Dis 1996; 23:1020-5. PMID:8922796; http://dx.doi.org/10.1093/clinids/23.5.1020.
21. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-7. PMID:8080497.
22. Toltzis P, Yamashita T, Vilt L, Green M, Morrissey A, Spinner-Block S, et al. Antibiotic restriction does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit. Crit Care Med 1998; 26:1893-9. PMID:9824085; http://dx.doi.org/10.1097/00003246-199811000-00035.
23. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003; 36:440-6. PMID:12567301; http://dx.doi.org/10.1086/346153.
24. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011; 6(Suppl 1):S4-15. PMID:21225949; http://dx.doi.org/10.1002/jhm.881.
25. McGowan JE. Antimicrobial stewardship--the state of the art in 2011: focus on outcome and methods. Infect Control Hosp Epidemiol 2012; 33:331-7. PMID:22418627; http://dx.doi.org/10.1086/664755.
26. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Almeida JN Jr., Félix CdaS, et al. Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis 2011; 15:1-5. PMID:21412581.
27. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-6. PMID:19273670; http://dx.doi.org/10.1128/AAC.01535-08.
28. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima ALL, et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents 2012; 39:11-5. PMID:22047702; http://dx.doi.org/10.1016/j.ijantimicag.2011.08.018.
29. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect 2008; 57:123-7. PMID:18644627; http://dx.doi.org/10.1016/j.jinf.2008.06.001.
30. Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE. Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs? Clin Infect Dis 2012; 55:587-92. PMID:22615329; http://dx.doi.org/10.1093/cid/cis494.
31. Martin CA, Armitstead JA, Mynatt RP, Hoven AD. Moving antimicrobial stewardship from restriction to facilitation. Am J Health Syst Pharm 2011; 68:109-10. PMID:21200053; http://dx.doi.org/10.2146/ajhp100272.
32. Goff D, Bauer K, West J. A cohort study comparing outcomes of extended-infusion doripenem to standard infusion imipenem for patients with invasive Pseudomonas aeruginosa infections [abstract]. Presented at: The 22nd European Congress of Clinical Microbiology and Infectious Diseases: March-April 2012; London, United Kingdom.